Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]

Details

Serval ID
serval:BIB_44ECB7C03967
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]
Journal
Revue medicale suisse
Author(s)
Nikolopoulou A., Galli-Vareia I., Stravodimou A., Sarivalasis A., Zaman K.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
15/05/2019
Peer-reviewed
Oui
Volume
15
Number
651
Pages
1027-1031
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
New targeted therapies modify therapeutic strategies for advanced stage breast and tubo-ovarian cancers. Chemotherapy and endocrine therapy remain the cornerstones of breast cancer treatment. Inhibitors of CDK4/6, mTOR and PI3K are associated with endocrine therapy to increase its effectiveness. PARP inhibitors outperform chemotherapy in BRCA1/2 mutation carriers. Immunotherapy integrates into the treatment of triple-negative cancers with very promising results. For tubo-ovarian cancers, the concept of « platinum-sensitive » has been tempered since the arrival of antiangiogenic treatment and PARP inhibitors that prolong the disease control not only in patients with BRCA1/2 mutation, but also in others.
Keywords
Antineoplastic Agents, Hormonal/therapeutic use, Breast Neoplasms/genetics, Breast Neoplasms/therapy, Female, Genes, BRCA1, Genes, BRCA2, Humans, Ovarian Neoplasms/genetics, Ovarian Neoplasms/therapy, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Pubmed
Create date
24/08/2021 11:38
Last modification date
19/09/2021 15:59
Usage data